ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer
By Dr. Matthew Watson
LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the TRYbeCA-1 Phase 3 trial in second-line pancreatic cancer.
View original post here:
ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer
- 001 Eton Pharmaceuticals Announces Closing of Public Offering [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 002 Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute... [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 003 Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 004 Stabilization measures taken [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 005 Coherus BioSciences Announces New Employment Inducement Grants [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 006 Biomerica Reports Fiscal 2021 1st Quarter Financial Results [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 007 German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 008 Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 009 SPACs Show Investors Faster, Simpler Way to Go Public [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 010 Psychedelics Experiencing Renaissance, Offer Tremendous Treatment Potential [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 011 Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020 [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 012 Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 013 Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 014 CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 015 Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 016 Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 017 Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 018 Theratechnologies Appoints Two New Board Members [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 019 Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 020 First Patient Dosed in Phase II Trial to Treat Complications in COVID-19 [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 021 Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 022 Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 023 UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 024 Replimune Appoints Tanya Lewis to the Board of Directors [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 025 ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 026 Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 027 Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020 [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 028 Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 029 Orion upgrades full-year outlook for 2020 [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 030 Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 031 Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR... [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 032 Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 033 22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and... [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 034 Rafarma Closes Biocogency Merger [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 035 Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020 [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 036 Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 037 Marrone Bio Innovations Issues Shareholder Letter and Provides Operational Update [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 038 Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 039 Cocrystal Pharma Provides Update on Influenza A Program [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 040 Reflect Scientific Awarded Patent for COVID Vaccine Capable- Self Powered, Low Temperature Controlled Bulk Shipping System [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 041 Athira Pharma to Host Educational Webinar on the Predictive Nature of P300 to Determine Clinical Benefit of Alzheimer’s Disease Treatments [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 042 Data to Be Presented at IDWeek™ 2020 Demonstrate the Economic and Clinical Burden of Respiratory and Multi-Virus Infections in Allogeneic... [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 043 TG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients... [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 044 BridgeBio Pharma, Inc. and the University of Colorado Anschutz Medical Campus Collaborate to Advance Medicines for Genetically Driven Diseases [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 045 AGTC to Participate in Cantor Fitzgerald Virtual Panel: Key Considerations for Gene Therapy Manufacturing and Platforms [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 046 Salk Institute and BridgeBio Pharma Collaborate to Advance Therapies for Genetically Driven Disease [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 047 Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19 [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 048 CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 049 Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2020 Annual Meeting [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 050 ADMA Biologics Announces Presentation on Respiratory Viral Infections and New Data on S. Pneumoniae at IDWeek 2020 [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 051 ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 052 SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 053 MediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 054 Syneos Health® Launches Kinetic™ Omnichannel Capability to Accelerate Modern Customer Engagement [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 055 Interim report for the first nine months of 2020 [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 056 PCI Biotech: Preclinical research collaboration with big pharma ended [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 057 Orion Group Interim Report 1-9/2020 [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 058 Idorsia successfully completes capital increase with gross proceeds of CHF 535.5 million [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 059 MDxHealth Provides Q3-2020 Business Update [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 060 Burning Rock to Present Data on Its Early Detection ELSA-seq at ESMO Asia Virtual Congress 2020 [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 061 Nicox Selects Development Candidate in a New Class of NO-mediated Intraocular Pressure (IOP) Lowering Agents [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 062 Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 063 Bone Therapeutics SA: Information on the total number of voting rights and shares [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 064 Genocea to Host Third Quarter 2020 Corporate Update Conference Call & Webcast [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 065 First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 066 KBP Biosciences Announces Data Presentation at the American Society of Nephrology Annual Meeting [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 067 Indus Holdings, Inc. Welcomes Bruce Gates to Board of Directors; Announces Results of Annual Shareholder Meeting [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 068 Coherus BioSciences to Report Third Quarter Financial Results on November 5th [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 069 BioCryst to Report Third Quarter 2020 Financial Results on November 5 [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 070 Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020 [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 071 Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 072 Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 073 Shockwave Medical Announces VIVA20 Investor Update and Conference Call Discussing Third Quarter 2020 Results [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 074 Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 075 X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020 [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 076 Retrophin Announces Agreement to Acquire Orphan Technologies [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 077 Evelo Biosciences to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020 [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 078 ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors Announcing First Preclinical Proof of Concept in Proprietary... [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 079 Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 080 Update on current trading for Q3 2020 and updated full-year outlook for 2020 [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
Global News Feed
Comments Off on ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer |
December 14th, 2020
This author published 6272 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research